Pancreatic Cancer
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
Advertisement
Expert Interviews on GI Oncology
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.